Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Lexaria Bioscience (LEXX) over the last 15 years, with Q4 2025 value amounting to $3.5 million.

  • Lexaria Bioscience's Cash from Financing Activities fell 2005.21% to $3.5 million in Q4 2025 from the same period last year, while for Nov 2025 it was $5.2 million, marking a year-over-year decrease of 5970.15%. This contributed to the annual value of $6.0 million for FY2025, which is 4138.59% down from last year.
  • Latest data reveals that Lexaria Bioscience reported Cash from Financing Activities of $3.5 million as of Q4 2025, which was down 2005.21% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Lexaria Bioscience's Cash from Financing Activities ranged from a high of $9.4 million in Q1 2021 and a low of -$121687.0 during Q3 2023
  • For the 5-year period, Lexaria Bioscience's Cash from Financing Activities averaged around $2.2 million, with its median value being $1.7 million (2023).
  • Over the last 5 years, Lexaria Bioscience's Cash from Financing Activities had its largest YoY gain of 1537506.25% in 2023, and its largest YoY loss of 98600.62% in 2023.
  • Lexaria Bioscience's Cash from Financing Activities (Quarter) stood at -$10987.0 in 2021, then dropped by 1.98% to -$11205.0 in 2022, then surged by 16337.13% to $1.8 million in 2023, then surged by 138.84% to $4.3 million in 2024, then decreased by 20.05% to $3.5 million in 2025.
  • Its last three reported values are $3.5 million in Q4 2025, $1.7 million for Q2 2025, and $11720.0 during Q1 2025.